Targeted inhibition of metabolic pathways to enhance radiopharmaceutical therapy
Targeted inhibition of metabolic pathways to enhance radiopharmaceutical therapy
批准号:
10577794
负责人:
Sangeeta Ray
金额:
$22.51万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-03-01 至 2024-02-29
关键词:
AddressAdoptedAdoptionAdverse effectsAlpha ParticlesAngiogenesis InhibitionAntigen TargetingBeta ParticleBiological AssayBlood VesselsCell LineCell SurvivalCell surfaceCellsClear cell renal cell carcinomaClinicalCombined Modality TherapyDNA DamageDNA RepairDNA Sequence AlterationDataDiseaseFOLH1 geneFunctional disorderGlutamatesGlutaminaseGlutamineGoalsHumanImageImmune checkpoint inhibitorImmunotherapyIn VitroInjectableInvadedIonizing radiationLabelLacrimal gland structureLow Dose RadiationMalignant NeoplasmsMalignant neoplasm of prostateMetabolic PathwayMetabolismMinorityModelingMolecularMutationNeoplasm MetastasisNeuroendocrine TumorsNucleotidesNutrientPathway interactionsPatient-Focused OutcomesPatientsPhase I/II Clinical TrialProcessProductionRadiationRadiation therapyRadioisotopesRadiopharmaceuticalsRadiosensitizationReactionReactive Oxygen SpeciesReduced GlutathioneRenal carcinomaResearchResistanceResistance developmentRoleSalivary GlandsSolid NeoplasmTestingTherapeuticTherapeutic AgentsTranslatingTranslationsTreatment FailureTumor Cell InvasionWorkangiogenesiscancer carecancer cellcastration resistant prostate cancercell killingclinically significantefficacy evaluationexperienceimplantationimprovedin vivoinhibitorneoplastic cellneovasculaturenoveloverexpressionparticlepatient derived xenograft modelphase III trialpre-clinicalpreventprognostic indicatorprogramsradiation deliveryradioresistantresponsescaffoldsmall moleculestandard of caresynergismtheranosticstranslational approachtreatment responsetumortumor growthtumor hypoxiatumor metabolismtumor microenvironmentuptake
中文摘要
谷氨酰胺是参与癌症新陈代谢的几个方面的主要营养物质。谷氨酰胺酶1(GLS1)启动
通过将谷氨酰胺转化为谷氨酸的过程,谷氨酸随后被用于支持
肿瘤细胞存活率。因此,抑制GLS1是治疗谷氨酸依赖肿瘤的一种很有前途的方法。
在这里,我们集中于靶向抑制GLS1,以提供一种新的策略,以增强前列腺特异性的效果
以膜抗原为基础的放射药物治疗转移性透明细胞肾细胞
癌(MRCC)。MRCC是致命的,5年存活率只有12%。虽然使用检查站进行免疫治疗
抑制剂已经显示出改善了总体存活率,但只有少数患者有可靠的反应。PSMA
在侵袭性肾细胞癌的新生血管中高表达,是一个负面的预后指标。
由于肿瘤新生血管是已批准的治疗肾细胞癌的靶点,我们假设
PSMA-RPT可作为一种新的有效的抗血管放射治疗方法。
许多癌症相关突变通过增加谷氨酰胺利用率来重新编程肾细胞癌的新陈代谢
通过GLS1。抑制GLS1通过减少核苷酸的产生和减少而减少mRCC中的DNA修复
减少谷胱甘肽的合成,同时独立地使肿瘤细胞容易受到DNA损伤。我们
假设抑制GLS1将通过诱导对癌症的进一步DNA损伤来增强PSMA-RPT
细胞。GLS1的抑制作用一般没有用RPT进行评估,也没有具体地在PSMA-RPT中进行评估。这个
临床测试的GLS1抑制剂和PSMA-RPT的可获得性使这一组合方法迅速
可翻译的。我们发现了小分子PSMA靶向,特别是用于成像,并开发了
多年来一直使用相应的放射治疗药物。我们最近翻译了一个优化的177Lu标记的β-
用于治疗前列腺癌的粒子发射化合物(PSMA-R2/L1)。在保持肿瘤摄取的同时,我们的
在人体研究中,化合物显示唾液腺摄取显著低于现有药物,这表明
225Ac-L1联合PSMA-RPT将改善α颗粒放射治疗的治疗窗。我们计划
评估177Lu-L1和225Ac-L1粒子的不同放射生物学效应,包括DNA
肾细胞癌低氧肿瘤微环境中的损伤活性。我们已经培育了几个肾细胞癌细胞系
具有可变GLS1和PSMA水平的体外和肿瘤模型以及患者驱动的肿瘤模型
概念研究。具体目的:目的1.评价177Lu-L1或225Ac-L1与GLS1联合应用的疗效
体外抑制物。目的2.评价177Lu-L1或225Ac-L1与GLS1抑制剂联合应用的体内疗效
在相关肿瘤模型中原位种植。如果成功,我们的研究可能会在近期和
对改善患者预后有重大影响。
英文摘要
Glutamine is a major nutrient involved in several aspects of cancer metabolism. Glutaminase1 (GLS1) initiates
that process by converting glutamine to glutamate that is subsequently used in multiple reactions that support
tumor cell survival. Accordingly, GLS1 inhibition is a promising approach to treat tumors dependent on glutamate.
Here we focus on targeted inhibition of GLS1 to provide a new strategy to enhance the effect of prostate-specific
membrane antigen-based radiopharmaceutical therapy (PSMA-RPT) to treat metastatic clear cell renal cell
carcinoma (mRCC). mRCC is lethal, with a 5-year survival of only 12%. Although immunotherapy with checkpoint
inhibitors has demonstrated improved overall survival, only a minority of patients reliably respond. PSMA
displays high expression within the neovasculature of aggressive mRCC, and is a negative prognostic indicator.
Because tumor neovasculature is an established target for approved therapies for mRCC, we hypothesize that
PSMA-RPT can be a new and effective anti-vascular radiotherapy.
Many cancer-associated mutations reprogram the metabolism of mRCC with increased glutamine utilization
through GLS1. Inhibition of GLS1 reduces DNA repair in mRCC through decreased nucleotide production and
reduces glutathione synthesis while independently making the tumor cells vulnerable to DNA damage. We
hypothesize that inhibition of GLS1 will enhance PSMA-RPT by inducing further DNA damage to the cancer
cells. Inhibition of GLS1 has not been evaluated with RPT in general, or in PSMA-RPT, specifically. The
availability of clinically tested GLS1 inhibitors and PSMA-RPT renders this combined approach rapidly
translatable. We discovered small-molecule PSMA targeting, particularly for imaging, and have developed the
corresponding radiotherapeutic agents over many years. We recently translated an optimized 177Lu-labeled β-
particle-emitting compound (PSMA-R2/L1) for treating prostate cancer. While maintaining tumor uptake, our
compound showed significantly lower salivary gland uptake than existing agents in human studies, suggesting
that PSMA-RPT with 225Ac-L1 will improve the therapeutic window of α-particle-based radiotherapy. We plan to
evaluate 177Lu-L1 and 225Ac-L1 because of the different radiobiologic effects of the particles, including DNA
damage activity in the hypoxic tumor microenvironment of mRCC. We have developed several mRCC cell lines
in vitro and tumor models with variable GLS1 and PSMA levels and a patient-drived tumor model for a proof-of-
concept study. Specific Aims: Aim 1. To access the efficacy of 177Lu-L1 or 225Ac-L1 in combination with a GLS1
inhibitor in vitro. Aim 2. To assess the efficacy of 177Lu-L1 or 225Ac-L1 in combination with a GLS1 inhibitor in vivo
in relevant tumor models in orthotopic implantation. If successful, our research may have a near-term and
significant impact on improving patient outcomes.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Targeted inhibition of metabolic pathways to enhance radiopharmaceutical therapy
-
批准号:10356588
-
项目类别:
-
资助金额:$19.14万
-
财政年份:2022
-
负责人:Sangeeta Ray
-
依托单位:
PSMA-based MR Imaging and Therapy of Prostate Cancer
-
批准号:8490730
-
项目类别:
-
资助金额:$11.6万
-
财政年份:2011
-
负责人:Sangeeta Ray
-
依托单位:
PSMA-based MR Imaging and Therapy of Prostate Cancer
-
批准号:8294527
-
项目类别:
-
资助金额:$11.6万
-
财政年份:2011
-
负责人:Sangeeta Ray
-
依托单位:
PSMA-based MR Imaging and Therapy of Prostate Cancer
-
批准号:8688927
-
项目类别:
-
资助金额:$11.6万
-
财政年份:2011
-
负责人:Sangeeta Ray
-
依托单位:
PSMA-based MR Imaging and Therapy of Prostate Cancer
-
批准号:8044425
-
项目类别:
-
资助金额:$11.6万
-
财政年份:2011
-
负责人:Sangeeta Ray
-
依托单位:
海外基金